ArticleACS applied materials & interfaces2026
Hydroxycitrate is a Unique Inhibitor of Pathologically-Relevant Brushite Crystallization.
Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The unique interactions between (macro)molecules and the surfaces of crystalline materials is a common mechanism for controlling the formation of natural, biological, and synthetic crystals. These species, generally referred to as modifiers, can either inhibit or promote crystallization in ways that achieve properties unattainable by alternative processes, or alter nucleation to produce metastable polymorphs or solvates. In the field of pathological crystallization, modifiers can be native species or rationally designed molecules for the therapeutic purpose of suppressing crystal nucleation and/or growth. Here, we assess the effects of hydroxycitrate as a modifier of brushite (calcium phosphate dihydrate) crystallization and demonstrate its superior efficacy as an inhibitor compared to citrate, its molecular analogue present in urine naturally and commonly administered as a preventative therapy for calcium-based kidney stones. Using a combination of bulk crystallization, microfluidics, and atomic force microscopy, we show that hydroxycitrate is capable of completely suppressing brushite nucleation and operates as an effective growth inhibitor at concentrations nearly one order of magnitude lower than citrate. Our findings reveal a concentration-dependent mode of action for hydroxycitrate which at low supersaturation induces the formation of defects (i.e., surface voids) far from nucleation centers that are not observed at high supersaturation. Kinetic studies reveal that hydroxycitrate fully suppresses two of the three principal growth directions, whereas citrate only suppresses one direction. For crystallographic growth directions where modifiers are moderately effective, both citrate and hydroxycitrate inhibit crystallization by as much as 60%, leading to markedly reduced rates of growth and concomitant changes in crystal habit. Collectively, the results of this study open avenues into the design of potent inhibitors of pathological crystallization with potential implications for other biominerals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.